Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 4,4-Difluoro-Piperidinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4,4-Difluoro-Piperidinium SCHEMBL27142480 | 1.00 | HIF1A (0.33) | — | |
| 4,4-Difluoro-Piperidinium SCHEMBL13457 | 0.96 | — | — | |
| 4,4-Difluoro-Piperidinium SCHEMBL19410291 | 0.93 | — | — | |
| 4,4-Difluoro-Piperidinium SCHEMBL29154751 | 0.93 | — | — | |
| 4,4-Difluoro-Piperidinium SCHEMBL1000443 | 0.93 | — | — | |
| 4,4-Difluoro-Piperidinium SCHEMBL22288728 | 0.90 | — | — | |
| 4,4-Difluoro-Piperidinium SCHEMBL28957490 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL937458 | 0.88 | CXCR4 (0.35) | — | |
| Hydrochloric Acid SCHEMBL3662239 | 0.86 | CXCR4 (0.33) | — | |
| SCHEMBL2519854 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2056 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619919-A | Preparation method of 1- (azetidine-3-yl) -4, 4-difluoropiperidine hydrochloride | 宁波职业技术学院 | 2024-09-10 | — | — | CN | claimed |
| CN-115621548-B | Preparation method and application of novel piperidine ionic liquid electrolyte | 深圳大学 | 2024-04-30 | — | — | CN | claimed |
| CN-114409636-B | Quinazolinone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 沈阳药科大学 | 2023-04-18 | — | — | CN | claimed |
| CN-115621548-A | Preparation method and application of novel piperidine ionic liquid electrolyte | 深圳大学 | 2023-01-17 | — | — | CN | claimed |
| CN-111116456-B | Preparation method of 4, 4-difluoropiperidine hydrochloride | 南通华祥医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-111116456-A | Preparation method of 4, 4-difluoropiperidine hydrochloride | 海门华祥医药科技有限公司 | 2020-05-08 | — | — | CN | claimed |
| US-12637445-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098600-A1 | FORMULATION CONTAINING HETEROCYCLIC COMPOUND OR COMPLEX FORMED FROM HETEROCYCLIC COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALT, PREPARATION METHOD THEREFOR, AND USE THEREOF | 湖北生物医药产业技术研究院有限公司 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026098592-A1 | USE OF HETEROCYCLIC COMPOUND AND COMPLEX FORMED BY HETEROCYCLIC COMPOUND AND PHARMACEUTICALLY ACCEPTABLE ACID | 湖北生物医药产业技术研究院有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4568960-B1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-20260098029-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2004056815-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | WO | disclosed |
| EP-1433788-A1 | Pyrazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-06-30 | — | — | EP | disclosed |
| US-6710040-B1 | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors | PFIZER INC. | 2004-03-23 | — | — | US | disclosed |
| WO-2003101958-A2 | FLOURINATED CYCLIC AMIDES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003089409-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
| US-5350743-A | Treatment of osteoporosis | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1994-09-27 | — | — | US | disclosed |
| EP-0498424-A1 | Bisphosphonic acid derivatives and bone resorption inhibitors containing them | Kaken Pharmaceutical Co., Ltd. (JP) | 1992-08-12 | — | — | EP | disclosed |